Connect
← Return to Genetic testing for breast cancer Revised guidelines
Discussion
Genetic testing for breast cancer Revised guidelines
Breast Cancer | Last Active: Jul 26, 2022 | Replies (41)Comment receiving replies
Here's some more info on the "low" HER2.
The clinical trial is called: DESTINY-Breast04
https://ascopost.com/news/june-2022/fam-trastuzumab-deruxtecan-nxki-doubles-progression-free-survival-in-her2-low-metastatic-breast-cancer/
Replies to "Here's some more info on the "low" HER2. The clinical trial is called: DESTINY-Breast04 https://ascopost.com/news/june-2022/fam-trastuzumab-deruxtecan-nxki-doubles-progression-free-survival-in-her2-low-metastatic-breast-cancer/"
Connect
It seems that this study pertains to metastatic cancers.
Except for this sentence at the beginning:
The use of fam-trastuzumab deruxtecan-nxki doubled progression-free survival compared with the standard-of-care treatment plus conventional chemotherapy.
But then it goes on to discuss benefits with metastatic so I think that is where it is being used.
I have made it 7 years so far. I have always wondered if my HER2 should have been treated! They have not yet determined the threshold for "low" but I am pretty sure I would be in that group with my mixed results and final pathology that was almost on the line.